Commercialization

Institute for Commercialization of Florida Technology Delivers Over $3.4 Billion Economic Impact

Thursday, December 2, 2021 - 10:10pm

The study measured economic impacts of the Florida Institute during FY 2020-21 to update prior years' studies and concluded that the organization's impact increased by $761 million to $3.4 billion.

Key Points: 
  • The study measured economic impacts of the Florida Institute during FY 2020-21 to update prior years' studies and concluded that the organization's impact increased by $761 million to $3.4 billion.
  • Florida Institute funded companies continue to raise investment capital, increase sales, create jobs, and bring innovative products to market.
  • The Florida Institute supports new companies in Florida that create sustainable jobs in knowledge-based industries driving the global economy.
  • Formed by the Florida Legislature in 2007, the Institute for Commercialization of Florida Technology supports and funds innovation companies that create clean jobs in new industries driving the global economy.

MIT Technology Review's inaugural TR35 Festival event kicks off online December 8, 2021

Thursday, December 2, 2021 - 2:47pm

CAMBRIDGE, Mass., Dec. 2, 2021 /PRNewswire/ -- MITTechnology Review's inaugural TR35 Festival takes place December 8, 2021.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 2, 2021 /PRNewswire/ -- MITTechnology Review's inaugural TR35 Festival takes place December 8, 2021.
  • The TR35 Festival is designed for those in technology who are passionate about building a better, more resilient world.
  • Sessions include Bringing your Innovation to Life, Scaling your Innovation, Paths to Commercialization, Proactively Building your Network, and more.
  • MIT Technology Review's mission is to bring about better-informed and more conscious decisions about technology through authoritative, influential, and trustworthy journalism.

Arterys Signs Global Distribution Agreement With iCAD, Inc. to Launch Its New Breast AI SaaS Solution

Tuesday, November 30, 2021 - 2:39pm

SAN FRANCISCO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Arterys, the world's leading vendor-neutral AI platform, today announced it signed a global distribution agreement with iCAD , a global medical technology leader providing innovative cancer detection and therapy solutions.

Key Points: 
  • SAN FRANCISCO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Arterys, the world's leading vendor-neutral AI platform, today announced it signed a global distribution agreement with iCAD , a global medical technology leader providing innovative cancer detection and therapy solutions.
  • This partnership will expand access to iCAD's industry-leading AI-powered breast health solutions via Arterys' FDA-cleared and CE-marked MICA platform to its installed base.
  • "Arterys is not an AI Marketplace company but an AI Platform company where we bring only the best-of-breed AI solutions together to work seamlessly within one user interface.
  • ProFound AI for DBT was the first AI cancer detection software for DBT to be cleared by the FDA.

DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application

Tuesday, November 30, 2021 - 10:03am

The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.

Key Points: 
  • The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto.
  • The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a portfolio of different indications.
  • "We are delighted to see this partnership emerging between PentixaPharm, CanProbe, and UHN", adds Luke Brzozowski, Senior Director, Techna and Diagnostics Innovation, University Health Network.

MHI Thermal Systems Receives '2021 Minister of the Environment Award for Climate Action' for 'Q-ton Circulation' Air-to-Water Heat Pump

Thursday, November 25, 2021 - 8:04am

The award ceremony will take place on December 8 at the Tokyo Big Sight exhibition hall.

Key Points: 
  • The award ceremony will take place on December 8 at the Tokyo Big Sight exhibition hall.
  • The Ministry of the Environment accolade marks the fourth award bestowed on the Q-ton Circulation.
  • In 2019, the new heat pump received the 47th Technology Award from the Japan Society of Refrigerating and Air Conditioning Engineers (JSRAE).
  • The 2021 award is MHI Thermal Systems' second to date: in 2019, the company received an Environment Minister's Award for Global Warming Prevention Activity for its centrifugal chiller ETI-Z Series that adopt a low-GWP refrigerant.

Making the Metaverse: Hardware Hurdles, Discussed by IDTechEx

Wednesday, November 24, 2021 - 11:08am

The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.

Key Points: 
  • The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.
  • The software for this is nearly there, but the hardware still has many hurdles to overcome.
  • The technological journey towards the hardware needed to create this hypothetical device presents even more compelling developments and complex challenges than the software.
  • Further details and downloadable sample pages for each report can be found on the IDTechEx website .

Making the Metaverse: Hardware Hurdles, Discussed by IDTechEx

Wednesday, November 24, 2021 - 11:08am

The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.

Key Points: 
  • The metaverse promises a step-change in how society communicates but, without the hardware technology, will ultimately remain a pipe dream.
  • The software for this is nearly there, but the hardware still has many hurdles to overcome.
  • The technological journey towards the hardware needed to create this hypothetical device presents even more compelling developments and complex challenges than the software.
  • Further details and downloadable sample pages for each report can be found on the IDTechEx website .

Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products

Monday, November 22, 2021 - 12:05pm

WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.

Key Points: 
  • WinRhoSDF is also used for suppression of Rhesus (Rh) Isoimmunization during pregnancy and other obstetric conditions in non-sensitized, Rho(D)-negative women.
  • "The acquisition of this FDA-approved commercial portfolio represents a critical strategic and synergistic transaction and growth driver for Kamada, said Amir London, Kamadas Chief Executive Officer.
  • To partially fund the acquisition costs, Kamada has secured a $40 million credit facility from Bank Hapoalim, Israels leading commercial bank.
  • Kamada Ltd. (the Company) is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease

Wednesday, November 17, 2021 - 12:00pm

Drugs with Fast Track designation may also qualify for accelerated approval and priority review of new drug applications.

Key Points: 
  • Drugs with Fast Track designation may also qualify for accelerated approval and priority review of new drug applications.
  • Pridopidine is currently being assessed in PROOF-HD (PRidopidine Outcome On Function in Huntington Disease), a global phase 3 clinical trial that very recently completed patient enrollment.
  • Receipt of Fast Track designation from the FDA underscores the urgency to address a significant unmet need for patients with Huntingtons Disease, said Dr. Michael R. Hayden, CEO and Founder of Prilenia.
  • Prilenia has been granted orphan drug designation for pridopidine for the treatment of HD in both the U.S. and Europe.

Every Body Eat Named the $1 Million Grand Prize Winner of the 2021 Grow-NY Global Food and Agriculture Business Competition

Thursday, November 18, 2021 - 7:53pm

Ball, Commissioner of the New York State Department of Agriculture and Markets, announced the recipients of the $3 million in prize money.

Key Points: 
  • Ball, Commissioner of the New York State Department of Agriculture and Markets, announced the recipients of the $3 million in prize money.
  • This included a $1 million grand prize, two $500,000 prizes and four $250,000 prizes.
  • Agriculture and Food Innovation Pushing the state-of-the-art in food and agriculture and contributing to making Upstate NY a global leader in agriculture and food innovation.
  • "We are absolutely honored to be selectedfrom such an incredible pool of food and agriculture start-upsas this year's $1 million top prize winner at Grow-NY," said Nichole Wilson, co-founder and president ofEvery Body Eat.